Hanmi Unveils Novel Obesity Drug 'HM17321' : A Game-Changer in Overcoming GLP-1-Associated Muscle Loss

Contributed by: PR Newswire

Images

PR Newswire associated0

Tags

Hanmi-Pharmaceutical

More Like This

HUADONG MEDICINE Announces Positive Phase I Results for Innovative Oral Small Molecule GLP-1 Receptor Agonist HDM1002

PR Newswire associated0

Gan & Lee Pharmaceuticals Announces Significant Progress on New Diabetes and Obesity Treatments at the American Diabetes Association's 84th Scientific Sessions

MRI-based muscle assessment - Determining the relationship between drug-induced weight reduction and muscle health (Photo: Business Wire)

Adapting To Change: New Focused Review in Circulation Explores The Relationship Between Weight Reduction and Muscle Health

PR Newswire associated0

Daewoong Pharmaceutical to Initiate Clinical Trials Early Next Year for Innovative 'GLP-1 Obesity Treatment' with Advanced Microneedle Technology for Sustained Weekly Efficacy

Credit: Collaboration with Dr. Ian J Neeland, University Hospitals Cleveland. Data from NCT03038620 (ClinicalTrials.gov identifier) analysed with AMRA® Researcher

AMRA Medical’s Muscle Composition Analysis Used to Evaluate the Effect of Liraglutide Treatment in Obesity

MHRA approves GLP –1 receptor agonist semaglutide to reduce risk of serious heart problems in obese or overweight adults

PR Newswire associated0

Gan & Lee Pharmaceuticals' Three Innovative Drugs: GZR18 Injection, GZR4 Injection, and GZR101 Injection Achieve Primary Endpoints in Phase 2 Clinical Studies

PR Newswire associated0

Gan & Lee Pharmaceuticals Announced Positive Phase 1 Results for Its Oral GLP-1 Receptor Agonist GZR18 Tablet in Healthy Participants, Demonstrating 4.16% Weight Reduction in Two Weeks